Sponsors / MLTX
MLTX

MoonLake Immunotherapeutics AG

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
9Trials in this database
13Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaNCT05322473MoonLake Immunotherapeutics AGPhase 2Completed2023-05-09Actual
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisNCT05640245MoonLake Immunotherapeutics AGPhase 2Completed2023-09-05Actual
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411379MoonLake Immunotherapeutics AGPhase 3Completed2025-08-14Actual
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411899MoonLake Immunotherapeutics AGPhase 3Completed2025-09-02Actual
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076MoonLake Immunotherapeutics AGPhase 3Active not recruiting2027-02-04Estimated
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089MoonLake Immunotherapeutics AGPhase 3Recruiting2027-01-15Estimated
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671MoonLake Immunotherapeutics AGPhase 3Active not recruiting2026-09-28Estimated
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaNCT07007637MoonLake Immunotherapeutics AGPhase 3Enrolling by invitation2028-06-13Estimated
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisNCT07223138MoonLake Immunotherapeutics AGPhase 3Enrolling by invitation2028-02-04Estimated

Latest recorded trial changes

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

NCT05640245 · MoonLake Immunotherapeutics AG

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Response Rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)

+ After

Measure: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12

Check registry source
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473 · MoonLake Immunotherapeutics AG

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Hidradenitis Suppurativa Clinical Response 75

+ After

Measure: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12

Check registry source